Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Merk

Showing results (31-40 of 165) with videos related to

Pageof 17
Sort By:
Chemmedchem|April 12, 2019
Design of Natural-Product-Inspired Multitarget Ligands by Machine LearningFrancesca Grisoni, Daniel Merk, Lukas Friedrich, et al.
Chemmedchem|October 25, 2018
Selective Optimization of Pranlukast to Farnesoid X Receptor ModulatorsSimone Schierle, Jurema Schmidt, Astrid Kaiser, et al.
Scientific Reports|November 9, 2018
Scaffold-Hopping from Synthetic Drugs by Holistic Molecular RepresentationFrancesca Grisoni, Daniel Merk, Ryan Byrne, et al.
Molecular Informatics|January 11, 2018
De Novo Design of Bioactive Small Molecules by Artificial IntelligenceDaniel Merk, Lukas Friedrich, Francesca Grisoni, et al.
Journal of Medicinal Chemistry|November 29, 2021
The Medicinal Chemistry and Therapeutic Potential of LRH-1 ModulatorsAlisa Lang, Laura Isigkeit, Manfred Schubert-Zsilavecz, et al.
Expert Opinion on Therapeutic Patents|November 16, 2012
Novel prostaglandin receptor modulators: a patent review (2002 - 2012) - part I: non-EP receptor modulatorsChristina Lamers, Daniel Flesch, Manfred Schubert-Zsilavecz, et al.
Journal of Medicinal Chemistry|September 19, 2025
Comparative Profiling and Chemogenomics Application of Chemical Tools for NR4A Nuclear ReceptorsSabine Willems, Vasily Morozov, Julian A Marschner, et al.
ACS Pharmacology & Translational Science|March 6, 2025
Comparative Evaluation and Profiling of Chemical Tools for the Nuclear Hormone Receptor Family 2Max Lewandowski, Romy Busch, Julian A Marschner, et al.
Expert Opinion on Therapeutic Patents|January 8, 2013
Novel prostaglandin receptor modulators--part II: EP receptor modulators; a patent review (2002 - 2012)Daniel Flesch, Daniel Merk, Christina Lamers, et al.
Journal of Medicinal Chemistry|February 25, 2021
Fragment-like Chloroquinolineamines Activate the Orphan Nuclear Receptor Nurr1 and Elucidate Activation MechanismsSabine Willems, Julia Ohrndorf, Whitney Kilu, et al.
Pageof 17

Showing results (31-40 of 165) with videos related to

Sort By:
Pageof 17
Chemmedchem|April 12, 2019
Design of Natural-Product-Inspired Multitarget Ligands by Machine LearningFrancesca Grisoni, Daniel Merk, Lukas Friedrich, et al.
Chemmedchem|October 25, 2018
Selective Optimization of Pranlukast to Farnesoid X Receptor ModulatorsSimone Schierle, Jurema Schmidt, Astrid Kaiser, et al.
Scientific Reports|November 9, 2018
Scaffold-Hopping from Synthetic Drugs by Holistic Molecular RepresentationFrancesca Grisoni, Daniel Merk, Ryan Byrne, et al.
Molecular Informatics|January 11, 2018
De Novo Design of Bioactive Small Molecules by Artificial IntelligenceDaniel Merk, Lukas Friedrich, Francesca Grisoni, et al.
Journal of Medicinal Chemistry|November 29, 2021
The Medicinal Chemistry and Therapeutic Potential of LRH-1 ModulatorsAlisa Lang, Laura Isigkeit, Manfred Schubert-Zsilavecz, et al.
Expert Opinion on Therapeutic Patents|November 16, 2012
Novel prostaglandin receptor modulators: a patent review (2002 - 2012) - part I: non-EP receptor modulatorsChristina Lamers, Daniel Flesch, Manfred Schubert-Zsilavecz, et al.
Journal of Medicinal Chemistry|September 19, 2025
Comparative Profiling and Chemogenomics Application of Chemical Tools for NR4A Nuclear ReceptorsSabine Willems, Vasily Morozov, Julian A Marschner, et al.
ACS Pharmacology & Translational Science|March 6, 2025
Comparative Evaluation and Profiling of Chemical Tools for the Nuclear Hormone Receptor Family 2Max Lewandowski, Romy Busch, Julian A Marschner, et al.
Expert Opinion on Therapeutic Patents|January 8, 2013
Novel prostaglandin receptor modulators--part II: EP receptor modulators; a patent review (2002 - 2012)Daniel Flesch, Daniel Merk, Christina Lamers, et al.
Journal of Medicinal Chemistry|February 25, 2021
Fragment-like Chloroquinolineamines Activate the Orphan Nuclear Receptor Nurr1 and Elucidate Activation MechanismsSabine Willems, Julia Ohrndorf, Whitney Kilu, et al.
Pageof 17